Facio expands Board
June 30, 2017
Facio Therapies announced today that Cord Dohrmann, David Mackay, and Chip Wilson have joined its Board. Facio’s Board was expanded in conjunction with the successful raise of €4.8M in equity that Facio announced on 20 June, 2017.
Cord Dohrmann is the Chief Scientific Officer and a member of the Management Board of Evotec, Facio’s strategic drug discovery partner. He also serves on the Supervisory Board of Eternygen GmbH. Cord has spent over 20 years in biomedical research at leading academic institutions and in the biotech industry. Before joining Evotec in 2010, he held various management positions including CEO at DeveloGen, where he led the company from a start-up to an internationally recognized metabolic disease company. Cord received his Ph.D. in Cell and Developmental Biology from Harvard Medical School in Boston, USA. He (co-)authored a number of scientific publications and is an inventor on several patents.
David Mackay held a number of key positions at Kellogg Company in the United States, Australia, the United Kingdom, and Ireland, retiring as president and chief executive officer. He was also a member of Kellogg Company's Board of Directors and Executive Management Committee. He holds a Bachelor’s degree in business from Charles Sturt University, Australia. Currently, David serves as Director at Clorox and Fortune Brands. David’s wife, Michelle, has FSHD.
Chip Wilson is an entrepreneur, visionary, business leader, and philanthropist. He founded the yoga-inspired clothing company, lululemon athletica, and is credited with starting the “athleisure” retail category, which has expanded into a $100-billion-a-year global business. More recently, he created a portfolio of companies called Hold It All, which directly reflects his diverse interests, personal vision and values. His philanthropic initiatives include imagine1day, a non-profit organization committed to bringing quality education to all Ethiopians by 2030, public arts and parks initiatives throughout Metro Vancouver, and The Chip and Shannon Wilson School of Design at Kwantlen Polytechnic University. Chip has FSHD.
Kees van der Graaf, Facio’s Chairman, commented: “We are proud that three business leaders of such distinction have agreed to join our Board. With a wealth of industry experience normally not available to early-stage biopharmaceutical companies, our Board is a strong force behind our efforts to bring causal and affordable therapies to all people with FSHD.”
FSHD (facioscapulohumeral dystrophy) is a muscle wasting disease, worldwide devastating the lives of about 700,000 people and those close to them. The loss of muscle strength has a huge impact on daily life. Living with FSHD means living with pain, fatigue, and social isolation. Above all, the future becomes uncertain because the course of the disease is unpredictable. About 20% of people with FSHD end up in a wheelchair. Currently, no therapy for FSHD is available other than forms of temporary symptomatic relief.
About Facio Therapies BV
Facio Therapies, established in 2014, is a Netherlands-based company with a single focus – to overcome FSHD by developing a causal therapy that restores the natural repression of the muscle-toxic protein, DUX4. Facio works with leaders in the field to develop an affordable FSHD therapy in the most expeditious fashion possible. Rooted in, and dedicated to working for the FSHD community, Facio’s business approach is to have a positive impact on lives rather than to maximize financial gain. Facio’s founders – Kees van der Graaf (Netherlands), Bill Moss (Australia), and Neil Camarta (Canada) – are business leaders from the FSHD community. Since inception, Facio has raised over €8M in equity funding, predominantly from FSHD-affected families, their friends, and FSHD foundations across the world.